Personal care giant Beiersdorf has acquired Belgian life-science outfit S-Biomedic NV, a frontrunner in the field of skin microbiome research.
Beiersdorf, which originally invested in S-Biomedic in 2018 as part of its corporate venture capital activities, said it will continue to be managed as a standalone entity under its existing microbiome programme and will complement the company’s own research activities in this field.
Founded by Veronika Oudova and Bernhard Paetzold in 2014, S-Biomedic researches the delicate balance of the skin’s microbiome and develops active ingredients for cosmetic products by making use of living skin bacteria.
“Our vision since 2014 when we started S-Biomedic has been to build and promote skin microbiome technologies and make them to the new frontier in skin health,” said Oudova.
“I am very excited that together with the team we have achieved a very important milestone on that journey. By joining Beiersdorf our novel approach has its path to consumers all over the world,” she added.
Jörn Hendrik Reuter, head of the Microbiome Accelerator at Beiersdorf, said: “We are pleased to welcome S-Biomedic and its dedicated team to the Beiersdorf Group to join forces in this dynamic and highly promising research area.
“The advances of S-Biomedic in biomedical research complement our own efforts in this field and open the door to develop products that work in harmony with the natural skin processes.”
The companies have agreed not to disclose the purchase price.
